“…A member of the neurotrophin family of growth factor proteins, BDNF binds to Tropomyosin receptor kinase B (TrkB) receptors on neurons of the central and peripheral nervous systems where it supports neuronal survival and encourages neurogenesis (Binder & Scharfman, 2004). BDNF has predominantly been treated as a biomarker of synaptic plasticity (Benedetti et al, 2017; Kim, Watt, Ceballos, & Sharma, 2019), and due to its secretion by activated lymphocytes and the ability of IL-6 and TNF-α to augment BDNF release from the nervous system (Jin, Sun, Yang, Cui, & Xu, 2019; Kraneveld et al, 2014), BDNF activity resides at the intersection of neural development, memory formation, and neuroimmunology (Bekinschtein, Cammarota, Izquierdo, & Medina, 2007; Calabrese et al, 2014; Kim et al, 2019). In addition to BDNF’s modulation of the immune axis, it has also been implicated in instigating dysregulation of the HPA axis, with elevated BDNF levels contributing to hyperactivity of the HPA axis – a common molecular change seen in ACE-exposed children (K. S. Dempster et al, 2021; Naert, Ixart, Maurice, Tapia-Arancibia, & Givalois, 2011).…”